Amgen Inc. (AMGN)
AMGN moved a median of +0.12% 30 minutes after news, and +0.25% by the close. How AMGN actually reacts to news — the realized, point-in-time move the market made, measured across 590 labeled events over the last three years with zero look-ahead.
AMGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 52% | 590 |
| 30-min | +0.12% | 59% | 590 |
| 60-min | +0.12% | 56% | 590 |
| to close | +0.25% | 58% | 584 |
| Middle 50% of AMGN reactions | -0.30% to +0.44% |
|---|---|
| Median reaction (30-min) | +0.12% |
| Measured reactions | 590 |
Half of all Amgen Inc. news events land between -0.30% and +0.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AMGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 52 | -0.00% | 50% | +0.37% |
| Analyst downgrades | 37 | -0.10% | 49% | -0.25% |
| Coverage initiations | 40 | -0.24% | 35% | -0.36% |
| Rating reiterations | 166 | -0.07% | 46% | +0.14% |
| Price-target raises | 79 | +0.01% | 51% | +0.47% |
| Price-target cuts | 26 | -0.07% | 35% | +0.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how AMGN ranks against every other measured name →
That’s how AMGN usually reacts — get an email when it moves on news →Email me when AMGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AMGN's baseline. Nothing else.
Recent AMGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 | Press release | Canada Newswire | +0.80% | +1.61% | |
| AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE | Press release | PR Newswire | +0.09% | +1.89% | |
| FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA® | Press release | PR Newswire | -0.18% | -0.20% | |
| AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE | Press release | PR Newswire | +0.69% | -1.39% | |
| IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER | Press release | PR Newswire | -1.65% | -3.85% | |
| AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE | Press release | PR Newswire | -0.29% | -0.35% | |
| AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE | Press release | PR Newswire | -0.25% | +0.39% | |
| TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS | Press release | PR Newswire | +0.53% | +0.90% | |
| A $10 Generic Cut LDL Cholesterol by 53%. Why Are Employers Being Pushed Toward $700-a-Month Drugs? | Press release | PR Web | -0.12% | -0.86% | |
| Form 10-Q AMGEN INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.06% | +3.78% | |
| AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS | Press release | PR Newswire | +5.06% | +3.78% | |
| Form 8-K AMGEN INC For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +5.06% | +3.78% | |
| Form 8-K AMGEN INC For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -0.16% | -2.48% | |
| AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND | Press release | PR Newswire | -0.28% | +0.75% | |
| POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE | Press release | PR Newswire | -0.95% | -2.02% | |
| AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS | Press release | PR Newswire | -0.95% | -2.02% | |
| Form 11-K AMGEN INC For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | -0.59% | -0.69% | |
| AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS | Press release | PR Newswire | +0.48% | -0.87% | |
| AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE | Press release | PR Newswire | +0.73% | +0.23% | |
| AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026 | Press release | PR Newswire | +0.46% | +3.12% | |
| EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER | Press release | PR Newswire | +0.60% | +0.64% | |
| AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE | Press release | PR Newswire | -0.35% | -0.90% | |
| Ember LifeSciences announces new strategic investments boosting Series A to $27M | Press release | PR Newswire | -0.53% | -1.02% | |
| Form 8-K AMGEN INC For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.44% | +2.25% | |
| AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH | Press release | PR Newswire | -0.45% | +0.25% | |
| Form 8-K AMGEN INC For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | +0.25% | |
| CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research | Press release | GlobeNewswire | +0.34% | +1.24% | |
| Wall Street's Cardiac Bet: Where Diagnostics Meet the Money | Press release | Canada Newswire | -0.23% | +1.31% | |
| AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE | Press release | PR Newswire | +0.08% | +0.67% | |
| AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR | Press release | PR Newswire | -0.64% | -0.67% | |
| Form 10-Q AMGEN INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.28% | +0.62% | |
| AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS | Press release | PR Newswire | -1.80% | -0.81% | |
| Form 8-K AMGEN INC For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | -0.81% | |
| AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS | Press release | PR Newswire | +0.90% | -0.63% | |
| AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER | Press release | PR Newswire | +0.26% | +0.70% | |
| Form 8-K AMGEN INC For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +0.70% | |
| Form DEFA14A AMGEN INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.44% | +0.53% | |
| Form DEFA14A AMGEN INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.54% | +0.80% | |
| Form DEF 14A AMGEN INC For: May 19 | SEC filing · Form DEF | SEC EDGAR | -0.79% | +1.22% | |
| Form DEFA14A AMGEN INC | SEC filing · Form DEFA14A | SEC EDGAR | -0.79% | +1.22% | |
| AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE | Press release | PR Newswire | -0.03% | -0.83% | |
| Form ARS AMGEN INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.07% | +0.32% | |
| REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS | Press release | PR Newswire | -0.46% | -0.80% | |
| AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE | Press release | PR Newswire | -0.31% | +1.46% | |
| AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND | Press release | PR Newswire | -0.30% | -2.02% | |
| AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE | Press release | PR Newswire | +0.17% | +0.61% | |
| Form 8-K AMGEN INC For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | +0.74% | |
| Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight | Press release | PR Newswire | -0.36% | +0.67% | |
| AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT | Press release | PR Newswire | -0.36% | +0.67% | |
| Form 10-K AMGEN INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.36% | +0.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AMGN section they belong to.
Where else AMGN is measured.
AMGN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BiondVax Pharmaceuticals Ltd. - American Depositary Shares (BVXV) | 592 | 0.00% | 38% |
| EGALET CORP COMMON (EGLT) | 591 | -0.21% | 40% |
| Thermo Fisher Scientific Inc (TMO) | 589 | +0.06% | 55% |
| Biofrontera AG - American Depositary Shares (BFRA) | 585 | 0.00% | 32% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Amgen Inc.'s median reaction calculated?
Every labeled AMGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 590 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 59% of AMGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AMGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.